Roche skin cancer drugs "too expensive", says UK cost agency

LONDON, June 16 (Reuters) - Roche's two-drug

combination of Cotellic and Zelboraf for melanoma was rejected

by Britain's healthcare cost agency NICE as "too expensive" on

Thursday, in contrast to the green light given in April to a

rival cocktail from Novartis.

Read more